Charité - Universitätsmedizin Berlin

Hospital


Location: Berlin, Germany (DE) DE

ISNI: 0000000122184662

ROR: https://ror.org/001w7jn25

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis (2020) Hohenester S, Kanitz V, Kremer A, Paulusma CC, Wimmer R, Kühn H, Denk G, et al. Journal article Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution Serio - Side Effect Registry in Immuno-Oncology (2020) Koutzamanidis R, Mentzer D, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel-Becker S, Pavel ME, et al. Conference contribution Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase (2020) Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, et al. Conference contribution Itching and Neurodermatitis: Results from the German Neurodermatitis Register TREATgermany (2020) Haufe E, Heinrich L, Weisshaar E, Abraham S, Heratizadeh A, Harder I, Kleinheinz A, et al. Conference contribution Scleroderma renal crisis: Risk factors for an increasingly rare organ complication (2020) Moinzadeh P, Kuhr K, Siegert E, Blank N, Sunderkoetter C, Henes J, Krusche M, et al. Journal article Sodium Accumulates in the Skin of Psoriasis Patients and in Mice with Psoriasis-Like Skin Disease (2020) Marko L, Wild J, Rakova N, Balogh A, Opitz E, Linz P, Birukov A, et al. Conference contribution